Testing two alternating chemotherapy drugs before pancreatic cancer surgery

This trial is testing a new approach to treating borderline resectable pancreatic cancer by alternating between two chemotherapy drugs: gemcitabine plus nab-paclitaxel and mFOLFIRINOX. Both of these medications are already FDA-approved for pancreatic cancer, but this study wants to see if switching back and forth between them before surgery might work better than using just one. The hope is that this approach will shrink the tumor more effectively, make it easier to remove surgically, and reduce the chance of cancer returning.

Currently, doctors use one of these two chemotherapy treatments as the standard approach before pancreatic cancer surgery. By alternating between the two medications, researchers believe patients may have a better chance of a successful surgery and longer-term survival, since each drug works slightly differently and may attack cancer cells the medication alone might miss.